At ESMO, Professor Markus Moehler, Head of the GI Oncology Unit at the University Medical Center Mainz, shared findings from the phase III RATIONAL 305 trial, which evaluated tislelizumab plus chemotherapy versus placebo plus chemotherapy in patients with metastatic gastric or gastroesophageal junction cancer (CPS ≥5).
The study showed a clear survival benefit for the tislelizumab combination. Importantly, patient-reported outcomes indicated that better quality of life was linked to longer survival—offering valuable insight into the role of longitudinal PROs in treatment response.
Professor Moehler also highlighted China’s growing role in global oncology trials and stressed the need for continued collaboration across regions to optimize outcomes in gastric cancer care.
